BioMarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted FCF per Share: R$1.32 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:B1MR34 BioMarin Pharmaceutical Inc BSP:B1MR34
67 GF Score
Price R$170.37
GF Value R$204.24
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted FCF per Share?

BioMarin Pharmaceutical BSP:B1MR34 67 Cyclically Adjusted FCF per Share is R$1.32 as of Jun. 2026. GuruFocus rates BSP:B1MR34 with a GF Score™ of 67/100 and a GF Value™ of R$204.24 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BioMarin Pharmaceutical's adjusted free cash flow per share for the three months ended in Jun. 2026 was R$1.764. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$1.32 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BioMarin Pharmaceutical was 17.00% per year. The lowest was -15.00% per year. And the median was 2.85% per year.

As of today (2026-08-19), BioMarin Pharmaceutical's current stock price is R$170.37. BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was R$1.32. BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is 129.07.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 111.30. And the median was 139.32.


BioMarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=170.37/1.32
=129.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of BioMarin Pharmaceutical was 582.55. The lowest was 111.30. And the median was 139.32.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Related Terms


BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.20 -2.93 -2.48 -1.95 0.31

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.76 -0.16 0.31 1.11 1.32

BSP:B1MR34 vs TECH, CYTK, SMMT: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted Price-to-FCF falls into.


BSP:B1MR34
67GF Score
BioMarin Pharmaceutical Inc BSP:B1MR34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioMarin Pharmaceutical's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.764/333.9520*333.9520
=1.764

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.354 241.428 -0.490
201612 -0.504 241.432 -0.697
201703 -1.354 243.801 -1.855
201706 -0.274 244.955 -0.374
201709 -0.037 246.819 -0.050
201712 -0.237 246.524 -0.321
201803 -0.676 249.554 -0.905
201806 -0.601 251.989 -0.796
201809 -0.031 252.439 -0.041
201812 0.079 251.233 0.105
201903 -0.919 254.202 -1.207
201906 -0.657 256.143 -0.857
201909 0.385 256.759 0.501
201912 -0.040 256.974 -0.052
202003 -0.773 258.115 -1.000
202006 -0.083 257.797 -0.108
202009 0.902 260.280 1.157
202012 -0.753 260.474 -0.965
202103 1.303 264.877 1.643
202106 0.767 271.696 0.943
202109 1.105 274.310 1.345
202112 -0.511 278.802 -0.612
202203 -0.972 287.504 -1.129
202206 0.380 296.311 0.428
202209 1.721 296.808 1.936
202212 -0.417 296.797 -0.469
202303 -1.322 301.836 -1.463
202306 0.589 305.109 0.645
202309 1.450 307.789 1.573
202312 -0.120 306.746 -0.131
202403 0.161 312.332 0.172
202406 1.302 314.175 1.384
202409 2.813 315.301 2.979
202412 2.563 315.605 2.712
202503 2.310 319.799 2.412
202506 2.362 322.561 2.445
202509 4.677 324.800 4.809
202512 0.776 324.054 0.800
202603 2.642 330.213 2.672
202606 1.764 333.952 1.764

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$1.32 mean?
BioMarin Pharmaceutical (BSP:B1MR34) has a Cyclically Adjusted FCF per Share of R$1.32 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share too high?
BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is R$1.32. Overall, BioMarin Pharmaceutical has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share compare to TECH and CYTK?
BioMarin Pharmaceutical's Cyclically Adjusted FCF per Share of R$1.32 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current Cyclically Adjusted FCF per Share is R$1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BSP:B1MR34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$204.24, compared to a current price of R$170.37 — trading 16.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is R$1.32. BioMarin Pharmaceutical's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For BioMarin Pharmaceutical (BSP:B1MR34), the current Cyclically Adjusted FCF per Share is R$1.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (BSP:B1MR34) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of R$170.37 is trading 16.6% below its estimated GF Value™ of R$204.24. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BSP:B1MR34:

  • Cyclically Adjusted FCF per Share: R$1.32
  • GF Value™: R$204.24 vs. price of R$170.37 (16.6% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the BSP:B1MR34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
67GF Score

Get the complete analysis for BSP:B1MR34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$170.37
Price
R$204.24
GF Value